Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer IndicationsElena Ardini, Arturo Galvani, Maria Menichincheri et al.|Molecular Cancer Therapeutics|2016Cited by 317
Identification of <i>N</i>,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase InhibitorMaria Gabriella Brasca, Marina Ciomei, Nadia Amboldi et al.|Journal of Medicinal Chemistry|2009Cited by 128
Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor EfficacyClara Albanese, Marina Ciomei, Fulvia Roletto et al.|Molecular Cancer Therapeutics|2010Cited by 63
Anti‐tumour efficacy on glioma models of <scp>PHA</scp>‐848125, a multi‐kinase inhibitor able to cross the blood–brain barrierClara Albanese, Marina Ciomei, Rachele Alzani et al.|British Journal of Pharmacology|2013Cited by 21
Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disordersMaria Gabriella Brasca, Daniele Donati, Paola Gnocchi et al.|Bioorganic & Medicinal Chemistry|2015Cited by 20